Showing results (91-100 of 154) with videos related to
Sort By:
Pageof 16
Virology|September 3, 2003
An in vitro Flaviviridae replicase system capable of authentic RNA replicationJ E Tomassini, E Boots, L Gan, et al.The American Journal of Cardiology|February 16, 2010
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemiaSergio Fazio, John R Guyton, Adam B Polis, et al.Journal of Clinical Lipidology|June 26, 2017
Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trialHarold E Bays, Mehul D Patel, Panagiotis Mavros, et al.La Radiologia Medica|January 1, 1983
[Total body irradiation in the preparation of leukemic patients for bone marrow transplantation]V Vitale, G Scielzo, G Ricci, et al.Bioorganic & Medicinal Chemistry Letters|December 4, 2003
Synthesis and evaluation of optically pure dioxolanes as inhibitors of hepatitis C virus RNA replicationSanjib Bera, Leila Malik, Balkrishen Bhat, et al.The American Journal of Cardiology|November 26, 2008
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart diseaseLawrence A Leiter, Harold Bays, Scott Conard, et al.Atherosclerosis|April 28, 2015
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patientsOlivier Descamps, Joanne E Tomassini, Jianxin Lin, et al.World Journal of Surgery|October 13, 2001
Safety of laparoscopic approach for acute cholecystitis: retrospective study of 609 casesB Navez, D Mutter, Y Russier, et al.Mayo Clinic Proceedings|December 15, 2006
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL studyRonald B Goldberg, John R Guyton, Theodore Mazzone, et al.Vascular Health and Risk Management|May 23, 2014
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the USElizabeth Marrett, Changgeng Zhao, Ning Jackie Zhang, et al.Pageof 16